Non-small cell lung cancer with synchronous brain metastases: Identification of prognostic factors in a retrospective multicenter study (HOT 1701)

被引:0
作者
Ohhara, Yoshihito [1 ]
Kojima, Tetsuya [2 ]
Honjo, Osamu [3 ]
Yamada, Noriyuki [4 ]
Sato, Toshitaka [2 ]
Takahashi, Hirofumi [5 ]
Takamura, Kei [6 ]
Takashina, Taichi [7 ]
Sukoh, Noriaki [8 ]
Tanaka, Hisashi [9 ]
Kawai, Yasutaka [10 ]
Fujita, Yuka [11 ]
Yokoo, Keiki [12 ]
Hommura, Fumihiro [13 ]
Harada, Toshiyuki [14 ]
Honda, Ryoichi [15 ]
Amano, Toraji [16 ]
Dosaka-Akita, Hirotoshi [1 ]
Oizumi, Satoshi [4 ]
Kinoshita, Ichiro [1 ]
机构
[1] Hokkaido Univ Hosp, Dept Med Oncol, North 14, West 5, Kita Ku, Sapporo, Japan
[2] KKR Sapporo Med Ctr, Dept Resp Med, Toyohira Ku, Sapporo, Japan
[3] Sapporo Minamisanjo Hosp, Dept Resp Med, Chuo Ku, Sapporo, Japan
[4] Natl Hosp Org Hokkaido Canc Ctr, Dept Resp Med, Kikusui, Japan
[5] Hokkaido Univ Hosp, Dept Resp Med, Kita Ku, Sapporo, Japan
[6] Obihiro Kosei Hosp, Dept Resp Med, Obihiro, Japan
[7] Iwamizawa Municipal Gen Hosp, Dept Resp Med, Iwamizawa, Japan
[8] Natl Hosp Org Hokkaido Med Ctr, Dept Resp Med, Nishi Ku, Asahikawa, Japan
[9] Hirosaki Univ, Grad Sch Med, Dept Resp Med, Hirosaki City, Japan
[10] Oji Gen Hosp, Dept Resp Med, Tomakomai, Japan
[11] Natl Hosp Org Asahikawa Med Ctr, Dept Resp Med, Asahikawa, Japan
[12] Teine Keijinkai Hosp, Dept Resp Med, Teine Ku, Sapporo, Japan
[13] Sapporo City Gen Hosp, Dept Resp Med, Chuo Ku, Sapporo, Japan
[14] Japan Community Healthcare Org Hokkaido Hosp, Ctr Resp Dis, Toyohira Ku, Sapporo, Japan
[15] Asahi Gen Hosp, Dept Resp Med, Chiba, Chiba, Japan
[16] Hokkaido Univ Hosp, Clin Res & Med Innovat Ctr, Kita Ku, Sapporo, Japan
关键词
brain metastasis; non-small cell lung cancer; prognostic factor; MUTATION STATUS; EGFR MUTATION; OSIMERTINIB; CARCINOMA; SURVIVAL; SYSTEM;
D O I
10.1093/noajnl/vdae168
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-small-cell lung cancer (NSCLC) is a very aggressive type of lung cancer that often spreads to the brain. The authors of this study wanted to better understand which factors determine how long a patient lives once NSLC metastasizes to the brain. To do this, the authors reviewed the medical records of 566 patients in Japan with metastases in their brains from NSCLC. Their results showed that, on average, patients lived for 11.8 months. They identified 6 factors that affected how long they lived. These factors included age, overall health status, the severity of the original lung cancer, genetic differences in the cancer, whether the cancer had spread to other parts of the body, and the total number of different metastases in the brain. Based on these factors, the authors identified 3 groups of patients, with those in the high-risk group having much shorter survival compared to those in the low-risk group.
引用
收藏
页数:9
相关论文
共 31 条
  • [1] Amin MB., 2017, (Eds.). AJCC Cancer Staging Manual (8th edition). Springer International Publishing: American Joint Commission on Cancer
  • [2] Early stage non-small cell lung cancer patients need brain imaging regardless of symptoms
    Ando, Takahiro
    Kage, Hidenori
    Saito, Minako
    Amano, Yosuke
    Goto, Yasushi
    Nakajima, Jun
    Nagase, Takahide
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (04) : 641 - 646
  • [3] Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system
    Barnholtz-Sloan, JS
    Sloan, AE
    Davis, FG
    Vigneau, FD
    Lai, P
    Sawaya, RE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 2865 - 2872
  • [4] Bhatt VR, 2017, J GLOB ONCOL, V3, P208, DOI 10.1200/JGO.2016.003392
  • [5] EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data
    Fan, Yun
    Xu, Xiaoling
    Xie, Conghua
    [J]. ONCOTARGETS AND THERAPY, 2014, 7 : 2075 - 2084
  • [6] A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?
    Han, Guang
    Bi, Jianping
    Tan, Wenyong
    Wei, Xueyan
    Wang, Xiaohong
    Ying, Xiaofang
    Guo, Xiaofang
    Zhou, Xiaoyi
    Hu, Desheng
    Zhen, Weining
    [J]. ONCOTARGET, 2016, 7 (35) : 56998 - 57010
  • [7] EGFR mutation status on brain metastases from non-small cell lung cancer
    Hsu, Fred
    De Caluwe, Alex
    Anderson, David
    Nichol, Alan
    Toriumi, Ted
    Ho, Cheryl
    [J]. LUNG CANCER, 2016, 96 : 101 - 107
  • [8] Validation of the Eighth Edition Clinical T Categorization System for Clinical Stage IA, Resected Lung Adenocarcinomas: Prognostic Implications of the Ground-Glass Opacity Component
    Kim, Hyungjin
    Goo, Jin Mo
    Kim, Young Tae
    Park, Chang Min
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) : 580 - 588
  • [9] Frequent Central Nervous System Failure After Clinical Benefit With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Korean Patients With Nonsmall-Cell Lung Cancer
    Lee, Young Joo
    Choi, Hye Jin
    Kim, Se Kyu
    Chang, Joon
    Moon, Jin Wook
    Park, In Kyu
    Kim, Joo-Hang
    Cho, Byoung Chul
    [J]. CANCER, 2010, 116 (05) : 1336 - 1343
  • [10] Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
    Lim, Zuan-Fu
    Ma, Patrick C.
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)